Posttranslational N-glycosylation of the hepatitis B virus large envelope protein by Lambert, Carsten & Prange, Reinhild
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Virology Journal
Open Access Research
Posttranslational N-glycosylation of the hepatitis B virus large 
envelope protein
Carsten Lambert* and Reinhild Prange
Address: Institute for Medical Microbiology and Hygiene, University of Mainz, Augustusplatz, D-55101 Mainz, Germany
Email: Carsten Lambert* - lambert@uni-mainz.de; Reinhild Prange - prange@uni-mainz.de
* Corresponding author    
Abstract
Background: The addition of N-linked glycans to proteins is normally a cotranslational process
that occurs during translocation of the nascent protein to the endoplasmic reticulum. Here, we
report on an exception to this rule occurring on the hepatitis B virus (HBV) large L envelope
protein that is a subject to co-plus posttranslational N-glycosylation.
Results: By using an improved detection system, we identified so far unrecognized, novel isoforms
of L. Based on mutational analyses, the use of N-glycosylation inhibitors, and pulse-chase studies,
we showed that these isoforms are due to posttranslational N-glycan addition to the asparagines 4
and 112 within the preS domain of L. While an inhibition of N-glycosylation and glycan trimming
profoundly blocked virus assembly and release, the posttranslational N-glycosylation of L itself was
found to be dispensable for HBV morphogenesis.
Conclusion:  These data together with previous results implicate that the N-glycosylation
requirements of virion release are due to functional inhibition of cell glycoproteins engaged by
HBV.
Background
N-glycosylation is known to possess important functions
for many proteins, as it affects protein folding, quality
control, sorting, degradation, secretion, and modulates
immune responses [1,2]. N-linked glycans are added to
proteins en bloc in the lumen of the endoplasmic reticu-
lum (ER) as presynthesized oligosaccharides. The reaction
is catalyzed by the oligosaccharyltransferase (OST)-com-
plex that links the glycan unit to the asparagine residue in
the target sequence N-X-T/S. As the OST-complex is asso-
ciated with the translocon, N-glycosylation normally
occurs cotranslationally when the nascent protein chain
grows into the ER lumen [1,2]. However, in the present
study we show that the large envelope protein of the hep-
atitis B virus (HBV) is also modified by posttranslational
N-glycosylation.
HBV encodes three envelope proteins, the L (large), M
(middle), and S (small) proteins, within one single open
reading frame by using three different in-frame translation
start codons and a common stop codon [3] (see Fig. 1A).
Accordingly, the sequence of the S protein is repeated at
the C-termini of M and L, which contain the additional N-
terminal preS2 or preS2 plus preS1 domains, respectively.
On biogenesis, all three proteins are cotranslationally
integrated into the ER membrane by the topogenic signals
of the S region concomitant with partial cotranslational
N-glycosylation in their S domains [4,5]. The M protein is
additionally modified by cotranslational N-glycosylation
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in its preS2 domain that specifically mediates its interac-
tion with the ER lectin calnexin [6], likely for glycan-
dependent quality control. In difference, thus far no N-
glycan addition had been recognized to occur in the preS1
and preS2 (preS) domains of the L protein, although L
also interacts with calnexin [7]. The absence of preS-
linked N-glycosylation had been attributed to the unusual
topogenesis of L, as its N-terminal preS domain is retained
on the cytosolic side of the ER membrane during cotrans-
lational translocation. Upon maturation, about half of the
L molecules then posttranslationally translocate their preS
region into the ER lumen thereby generating a dual trans-
membrane topology with bitopical essential functions,
like envelopment of the viral nucleocapsid and receptor
binding during HBV entry [8-11] (see Fig. 1B).
HBV formation strictly depends on a functional N-glyco-
sylation apparatus of the cell, since both the inhibition of
N-glycosylation and N-glycan processing by ER glucosi-
dases block virion egress [12-14]. By contrast, the release
of empty envelope subviral particles that are mainly
formed by the S protein and known to accompany HBV
morphogenesis does not require N-glycans [6,13]. Based
on these observations, the preS2-specific N-glycan of the
M protein was suggested to be the prime target for N-gly-
cosylation inhibitors that would provoke aberrantly
folded M polypeptides with the potential to block HBV
envelope and hence virus maturation [14]. Consistent
with this, a mutational inactivation of the preS2-specific
N-glycosylation sequon of M has been shown to prevent
virus release in one report [14]. Inconsistently, however,
several studies have documented that M is dispensable for
HBV morphogenesis [15-17] and thus leave the puzzle
why virus production may require the preS2-linked glycan
but does not need the M protein.
In this study we readdressed the role of N-glycosylation in
HBV maturation with special emphasis on the L envelope
protein. We provide first evidence that L is N-glycosylated
within its preS1 and preS2 domains in an uncommon
posttranslational manner. In order to solely examine the
impact of the preS-specific glycosylation of L on virus pro-
duction, we used an engineered in vitro-replication system
that allows to study HBV assembly in the absence of an
ongoing M protein synthesis. We found that mutational
inactivation of the L-specific glycosylation sites did not
affect virus maturation, whereas inhibitors of N-glycosyla-
tion and glycan trimming blocked virus production, thus
indicating that proper N-glycosylation and processing of
host cell components are involved in HBV multiplication.
Results
Detection of two novel L forms
In previous works we have been focusing on the dual
topology of the HBV L protein that is generated by partial
posttranslational translocation of its N-terminal preS
region across the ER membrane. In order to analyze the
orientation of preS relative to the membrane, we repeat-
edly used protease protection assays of microsome-associ-
ated L chains [9,11,18]. The utilization of microsomal
fractions purified from transfected cells instead of crude
cell lysates enabled us to identify so far undetected forms
of L. When microsomal fractions of COS-7 cells tran-
siently expressing the wild-type L protein were analyzed
by Western blotting with the L-specific antibody MA18/7,
L appeared in its characteristic doublet of a 39-kDa nong-
lycosylated (p39) and a 42-kDa single-glycosylated
(gp42) species due to partial cotranslational N-glycosyla-
tion in its S domain as expected (Fig. 2A). Importantly, we
could detect two additional forms of L with molecular
weights of about 48 kDa and 51 kDa that were missing in
control-transfected cells. To rule out that the appearance
of these novel forms was simply due to L synthesis in
monkey cells, the L expression profile was analyzed in
human HEK 293T cells transiently transfected with
pNI2.L. Thereby, we could confirm the presence of the
four specific L isoforms (Fig. 2A). To finally exclude that
these forms resulted from an artificial overexpression of L
in those cell lines, we investigated its expression pattern in
human liver cells, the natural host cells of HBV. Therefore,
HuH-7 cells were transfected with a cloned, replication-
competent HBV genome that drives L synthesis under the
control of its authentic promoter [19]. As shown in Fig.
2A, the four L-specific bands were again evident thus indi-
cating that they present bona fide L isoforms.
Novel L forms result from N-glycosylation
By using protease protection assays, we observed that the
novel L forms were resistant against proteolysis and hence
should have their preS domains orientated into the ER
lumen (data not shown). Therefore, we reasoned that the
higher molecular weights of the 48 kDa and 51 kDa L
derivatives might be due to modification with N-glycans
attached to the preS region that contains two potential
consensus motifs (N4 and N112; Fig. 1A). To test for N-
glycosylation, lysates of L-expressing HEK 293T cells were
treated with Peptide:N-Glycosidase F (PNGase F), an
enzyme that cleaves high mannose, hybrid and complex
oligosaccharides from N-linked glycoproteins. As shown
in Fig. 2B, PNGase F not only converted gp42 but also the
two additional forms to the nonglycosylated p39 form of
L. To verify these results, we analyzed the L expression
profile in the presence of tunicamycin, which prevents N-
glycosylation. As expected, treatment of L-expressing HEK
293T cells with tunicamycin inhibited the formation of
gp42, but, importantly, also the generation of the 48 kDa
and 51 kDa forms. Although these data pointed to differ-
ently N-glycosylated L chains, the 48 kDa and 51 kDa
forms could equally represent a single-glycosylated L
polypeptide carrying distinct oligosaccharide moietiesVirology Journal 2007, 4:45 http://www.virologyj.com/content/4/1/45
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due to processing of glycan structures in the Golgi stacks.
To examine whether the L forms had acquired complex
glycan chains, cellular extracts were treated with endogly-
cosidase H (Endo H) which cleaves N-glycans from the
high-mannose-type present on glycoproteins in the ER,
while glycans trimmed within the Golgi to complex/
hybrid structures are resistant to Endo H. This analysis
clearly revealed that all modified L forms were converted
by Endo H to the non-glycosylated p39 L polypeptide
(Fig. 2B), thus indicating that they did not resemble
Golgi-processed glycan derivatives. Together, these data
demonstrated additional N-glycosylation of L occurring
beyond its known glycosylation site at N309.
Novel L forms result from N-glycosylation within preS1 
and preS2
We next were interested to identify the N-glycan attach-
ment sites of L. Inspecting the primary sequence of L, we
noted the existence of three consensus motifs within its S
domain (N166, N222, N309) and two within preS (N4,
N112) (see Fig. 1A). Because the asparagine correspond-
ing to N309 of L is the only glycosylation target used in
the S protein and in the S region of M [20], a modification
at N166 or N222 of L appeared unlikely. Therefore, we
focused on the two motifs within its preS1 and preS2
region of L (N4, N112) and replaced both putative aspar-
agine acceptor residues by glutamines. After transient
expression of the wild-type L and L.N4, 112Q double
mutant in HEK 293T cells, lysates were mock-treated or
treated with PNGase F prior to L-specific immunoblot-
ting. As shown in Fig. 3, the combined mutation of the
two preS-specific glycan acceptor sites of L resulted in the
disappearance of the 48 kDa and 51 kDa forms. Unlike
the wild-type, the L.N4, 112Q mutant was made in only
non- and single-glycosylated forms (p39/gp42) with the
latter likely being modified at N309, as shown by PNGase
F treatment. To unequivocally determine whether both
potential preS targets became modified, the positions N4
and N112 were mutated and analyzed individually. For
facilitating the interpretation of the results, the S-specific
glycosylation site of L (N309) was mutated in addition.
The sole inactivation of this site (L.N309Q) yielded the
non-glycosylated p39 and two glycosylated forms of
about 45 kDa and 48 kDa, thus adding further evidence
for preS-linked glycosylation of L. Next, the individual N4
or N112 mutations were combined with the N309Q sub-
stitution (L.N4, 309Q and L.N112, 309Q, respectively),
thereby leaving only one preS-specific glycosylation site in
each mutant. Both L.N4, 309Q and L.N112, 309Q
mutants appeared in the non-glycosylated p39 and one
glycosylated gp45 form, indicating that each of the two N-
glycosylation sites within the preS domain of L became
modified. Of note, however, the N-glycans attached to N4
or N112 have higher molecular weights than the glycan
linked to N309.
N-glycosylation within preS1 and preS2 occurs 
posttranslationally
Since translocation of the preS domain of L into the ER
lumen proceeds in a posttranslational manner, we rea-
soned that preS-linked N-glycosylation could occur in a
posttranslational mode. Addressing this point, we per-
formed a kinetic analysis by using a recently established
stable EcR-LHA-293 cell line with controllable L expres-
sion [21]. The expression of L was pulse induced for 3 h
and the synthesized L population was then chased for dif-
ferent time periods in the presence of the protein synthe-
sis inhibitor cycloheximide. As shown in Fig. 4, L
synthesized during the pulse mainly appeared in its non-
glycosylated p39 and single-glycosylated gp42 forms due
to partial cotranslational N-glycosylation within its S
domain. Conversely, during chase, the intensities of these
bands decreased concomitant with the appearance of the
glycosylated 48 kDa and 51 kDa forms modified within
preS. Notably, the amount of these forms increased dur-
ing chase extensions which demonstrated that N-glycans
were added to N4 and N112 of L in an unconventional
posttranslational reaction.
Domain structure and transmembrane topology of the HBV  L envelope protein Figure 1
Domain structure and transmembrane topology of 
the HBV L envelope protein. (A) Schematic representa-
tion of L consisting of the preS1, preS2 and S domains. Num-
bers above the domains refer to the corresponding amino 
acids positions. The usage of the second and third start 
codons located at positions 109 and 164 of L leads to synthe-
sis of the M and S proteins, respectively, as denoted by 
arrows. Consensus sequences for N-glycosylation are indi-
cated by the corresponding asparagine (N) residue. (B) 
Mixed topology of L at the ER membrane. Upon cotransla-
tional membrane integration, the preS1 and preS2 domains 
of L are initially located on the cytosolic surface of the ER 
(Left). During maturation, about ~50% of the L molecules 
posttranslationally translocate their preS region into the ER 
lumen (Right). Partial cotranslational N-glycosylation occur-
ring at N309 is indicated by (¥).Virology Journal 2007, 4:45 http://www.virologyj.com/content/4/1/45
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Inhibition of N-glycosylation in the absence of the M 
protein inhibits HBV release
A previous report had shown that HBV release can be
blocked by mutation of the preS2-specific glycosylation
site (N112) within the viral envelope open reading frame
[14]. Because preS2-linked glycosylation of L was undis-
covered thus far, the observed block to virus release had
been attributed to an aberrant M protein defective in its
preS2-specific glycan that might act in a dominant nega-
tive manner during HBV envelope formation. However,
this proposal is in seemingly conflict with the observation
that M is dispensable for HBV production [15-17]. With
regard to the novel mechanism of posttranslational L gly-
cosylation described herein, we rather asked if preS2-spe-
cific glycosylation of L is instead involved in HBV
morphogenesis. To unequivocally address this point, it
was important to study HBV production in the absence of
an ongoing M expression. Therefore, we used transfection
of a cloned replication-competent HBV genome that is
deficient to drive envelope protein synthesis (HBV.env-).
This genome was complemented in trans by cotransfec-
tion with S and L expression vectors. To prevent M synthe-
sis from the complemented L expression vector, the start
codon of M was likewise ablated in this construct (Lo).
With this approach, we analyzed the effects of inhibitors
of the N-glycosylation pathway, like tunicamycin and the
α-glucosidase inhibitors castanospermine (CST) or N-
butyl-deoxynojirimycin (NB-DNJ), on HBV maturation.
Virus formation and release from transfected HuH-7 cells
were monitored by immunoprecipitation of cellular
supernatants with envelope-specific antisera, radioactive
labelling of the partially double-stranded viral genome by
the endogenous polymerase of the virus, and detection of
the isolated genome by agarose gel electrophoresis. Simi-
larly, intracellular nucleocapsid assembly was monitored
by using capsid-specific antibodies for immunoprecipita-
tion of cellular lysates prior to endogenous polymerase
reaction (EPR). The HBV.env-  construct  trans-comple-
mented with S alone was able to produce intracellular
nucleocapsids but failed to support virion formation as
expected (Fig. 5A). However, virus formation could be res-
cued by the coexpression of Lo, thus confirming that M is
dispensable for HBV production. Next, transfected cells
were subjected to inhibitors of the N-glycosylation
machinery. To control the fitness of the cells under drug
treatment, the secretion of HBV subviral S particles was
L is synthesized in differently modified forms due to N-glycosylation Figure 2
L is synthesized in differently modified forms due to N-glycosylation. (A) COS-7 cells and HEK 293T cells were 
either transfected with empty control plasmids (control, C) or transfected with vectors carrying the cloned L gene (L). HuH-7 
cells were transfected with a cloned replication-competent HBV genome (HBV). Two days after transfection, microsomal ves-
icles were prepared and analyzed by SDS-PAGE and L-specific immunoblotting with the preS1-specific monoclonal antibody 
MA18/7. (B) The EcR-LHA-293 cell line with inducible L expression was either mock-treated (control, C) or induced with 
PonA. Cell lysates were mock-digested or digested with PNGase F, tunicamycin, or Endo H, as denoted above each panel. Sam-
ples were resolved by SDS-PAGE and subjected to L-specific immunoblotting. The nonglycosylated p39 and single-glycosylated 
gp42 forms of L are indicated on the right of each panel, and arrows to the right point at the two novel forms of L.Virology Journal 2007, 4:45 http://www.virologyj.com/content/4/1/45
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monitored by ELISA, as the production and export of such
particles have been shown to remain unaffected by tuni-
camycin or α-glucosidase inhibitors [13]. As shown in Fig.
5A, prevention of N-glycosylation by tunicamycin almost
completely blocked virus release but also the secretion of
S as well as the production of intracellular nucleocapsids
which hinted to cytotoxic effects of this drug. By contrast,
the application of the α-glucosidase inhibitors NB-DNJ
and CST had no or only modest cytotoxic effects under the
assay conditions used, as evidenced by proper nucleocap-
sid assembly within such treated cells (Fig. 5A). Impor-
tantly, the level of virus export was strongly reduced by
treatment with both NB-DNJ and CST inhibitors.
Together, these results demonstrated that accurate N-glyc-
osylation and glycan processing are essential for efficient
HBV production even in the absence of the M envelope
protein.
Inhibition of posttranslational N-glycosylation of L does 
not inhibit HBV release
This prompted us to investigate whether posttranslational
preS N-glycosylation of L per se is involved in HBV mor-
phogenesis. As above, the HBV genomic construct defec-
tive in envelope protein synthesis (HBV.env-) was
cotransfected together with wild-type or mutant S and Lo
expression constructs in HuH-7 cells and intracellular
nucleocapsid assembly and release of virions into the
medium were monitored by the EPR assay. Because the
preS2-specific glycan acceptor residue (N112) of L is
located within a critical region involved in nucleocapsid
envelopment comprising amino acids 92 to 113 (corre-
sponding to 103 to 124 in HBV, subtype adw2) [17,22],
we created the substitution T114A that destroyed the gly-
cosylation consensus motif (N-X-S/T) without being part
of the nucleocapsid envelopment region. While the
Lo.N112Q variant had a negative phenotype as expected,
the Lo.T114A mutant still supported virus production and
thus even more efficiently as compared to the wild-type Lo
protein (Fig. 5B). Similarly, inactivation of the preS1-spe-
cific glycosylation site of L had no inhibitory effect on
virus formation, neither alone (Lo.N4Q) nor in combina-
tion with the preS2 glycan knockout mutation (Lo.N4Q,
T114A) (Fig. 5B). In accordance with published data [14]
we also found no influence on virion secretion when the
glycan acceptor residue in the S protein (N146Q) and in
the S domain of L (N309Q) was mutated simultaneously
(data not shown). Together, these results indicated that
posttranslational N-glycosylation of L as well as cotransla-
tional N-glycosylation of L and S are not required for HBV
maturation. Hence, the observed inhibitory effects of the
N-glycosylation motifs within preS1 and preS2 of L are modified by N-glycosylation Figure 3
N-glycosylation motifs within preS1 and preS2 of L are modified by N-glycosylation. HEK 293T cells were either 
mock-transfected (control) or with the wild-type and mutant L constructs, as denoted above each panel. Diagrams (Top) show 
the N-glycosylation sites (¥) remaining for each mutant and brackets ((¥)) indicate known partial usage at N309. Following 
transfection, cell lysates were mock-treated or digested with PNGase F prior to SDS-PAGE and L-specific immunoblotting 
analysis.Virology Journal 2007, 4:45 http://www.virologyj.com/content/4/1/45
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N-glycosylation-interfering drugs on virus production are
likely due to functional inhibition of host cell factors
engaged by HBV for its propagation.
Discussion
In this work we report that the HBV L envelope protein is
modified by N-glycosylation within its N-terminal preS1
and preS2 domains. As would be expected from the
unique L biogenesis and topology, these modifications
take place after completion of L synthesis and thus in a
posttranslational mode. In general, N-glycans are cotrans-
lationally transferred to the asparagine residue of the
sequon N-X-S/T as the growing polypeptide is translo-
cated from the ribosome into the ER lumen [1,2]. How-
ever, recent reports provided first hints for an exception to
this rule in such that N-glycans can be also added post-
translationally to polypeptides at least under artificial
conditions. For examples, posttranslational N-glycosyla-
tion had been observed for the aglycoinsulin receptor syn-
thesized in the presence of tunicamycin [23], for a
truncated form of the peptidylglycine α-amidating
monooxygenase [24], or in manosylphosphoryldolichol-
deficient mutant cells [25]. The human coagulation factor
VII is another substrate of posttranslational N-glycosyla-
tion which becomes modified within its very C-terminal
region, presumably because conformational constraints
do not favour a cotranslational N-glycan addition [26]. In
the case of the HBV L protein, the posttranslationally N-
glycosylated sites are located in its N-terminal domain but
first entered the ER lumen after chain termination
[9,11,18]. Hence, the data presented here pointed out the
potential of the cellular machinery to conduct N-glycan
attachment independently of protein translation.
Although the enzymes catalyzing the posttranslational N-
glycosylation of L remain to be characterized, it is tempt-
ing to speculate that the cellular OST-complex is responsi-
ble for this modification based on our mutagensis
analysis, the use of endoglycosidases and the use of tuni-
camycin, an inhibitor of the OST-driven N-glycosylation
reaction. Accordingly, completed L polypeptides that
posttranslationally translocate their preS domains into
the ER should still have access to the OST-complex even
after their uncoupling from the ribosome. In support of
this view, recent data suggested that the OST-complex
might associate with the translocon in either a ribosome-
dependent or ribosome-independent manner [27]. There-
fore, it seems possible that proteins which remain tran-
siently associated with the Sec61 translocon after chain
termination or even reassociate with this channel can
become N-glycosylated by OST. Based on pulse-chase
analysis, we have evidence that the HBV L protein indeed
is associated with the translocon for a prolonged time
(our unpublished observations), thus rendering this pro-
tein as a model substrate to further investigate the mecha-
nism(s) of posttranslational N-glycosylation uncoupled
from protein synthesis.
Because the L protein along with its split topology is a key
player in the HBV life cycle, and because N-glycans have
been shown to serve as folding and trafficking devices of
many glycoproteins [1,2], it appeared reasonable to
assume that the newly identified posttranslational N-gly-
cosylation of L may contribute to viral replication. Previ-
ous studies have well documented an extreme sensitivity
of HBV egress to inhibition of N-glycosylation and ER glu-
cosidase function. Mutational analyses of the S-specific N-
glycan site, modified in all three envelope proteins,
revealed that this site is dispensable for viral particle
release and therefore should not be targeted by N-glyco-
sylation-interfering drugs. Rather, the preS2-specific N-
glycan of M was claimed to be responsible for N-glycan-
dependent HBV maturation, as an inactivation of this
sequon by a single mutation (N-X-T to N-X-A) blocked
virus release [14]. Conversely, however, in two other
reports a disruption of this sequon showed no measurable
effects on virus production [17,22]. With regard to these
conflicting data of the role of the preS2-specific N-glycan
and of the M protein per se played during virus formation
[15,16], here we have examined the impact of posttrans-
lational N-glycosylation of L in HBV-replicating cells in
which M protein synthesis was blocked. A treatment of
these cells with the glucosidase inhibitors CST or NB-DNJ
significantly reduced HBV release without, notably, affect-
ing intracellular nucleocapsid assembly, implicating that
these drugs interfered with proper L protein folding, traf-
ficking and/or nucleocapsid envelopment. To our sur-
prise, however, the mutational inactivation of the preS-
N-glycosylation within the preS domain occurs posttransla- tionally Figure 4
N-glycosylation within the preS domain occurs post-
translationally. The inducible EcR-LHA-293 cell line was 
either mock-treated (lane 1) or treated with PonA for 3 h to 
pulse-induce L synthesis. After PonA removal, L was chased 
for the indicated time periods in the presence of cyclohex-
imide, and lysates were analyzed by SDS-PAGE and L-specific 
Western blotting. The nonglycosylated p39 and single-glyco-
sylated gp42 forms as well as the newly discovered isoforms 
of L are indicated at the right.Virology Journal 2007, 4:45 http://www.virologyj.com/content/4/1/45
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specific N-glycosylation sites of L, either individually or in
combination, did not diminish virus production.
Together, these results suggested that posttranslational N-
glycosylation of L itself is not necessary for HBV morpho-
genesis. Hence, the N-glycosylation requirements of vir-
ion release are likely due to modifications of cell
glycoproteins assisting in L envelope and/or virus matura-
tion. The search for such proteins is under active investi-
gation.
Rather, the posttranslationally added N-glycans may serve
other, yet to be determined functions in the HBV infection
cycle. Interestingly, in an early study characterizing the L
protein in secreted HBV particles, Heermann and co-
workers also detected protein bands of > 45 kDa in puri-
fied virus samples but not in preparations of subviral par-
ticles [31]. Based on this observation it is tempting to
speculate that L proteins with posttranslational glycan
additions in the preS-domain may be selectively incorpo-
rated into mature virion particles. With respect to L topo-
genesis, these glycan chains presumably are exposed on
the virus surface where they may contribute to virulence.
First experiments analyzing the glycosylation pattern of
secreted viral particles confirmed the existence of addi-
tional preS1-specific N-glycans (data not shown). For sev-
eral viruses, like HIV-1, Sindbis virus, Dengue virus,
human cytomegalovirus, hepatitis C virus, and Ebola
virus, the N-linked glycans in their envelope glycoproteins
have been shown to mediate host-cell recognition [28],
and ref. therein]. Therefore, one putative function of the
preS-linked glycans may reside in facilitating HBV binding
to liver cells. In support of this view, a deletion of amino
Systemic but not preS-specific inhibition of N-glycosylation reduces virus production Figure 5
Systemic but not preS-specific inhibition of N-glycosylation reduces virus production. (A) To investigate the 
impacts of glycosylation inhibitors on HBV formation in the absence of the M protein, HuH-7 cells were (co)transfected with a 
plasmid-based HBV genome defective in envelope protein synthesis (pHBV.env-), a vector encoding the L gene with inactivated 
start codons for M and S (Lo), plus an S expression vector. Upon transient expression, cells were treated with the indicated 
drugs for 70 h. Secretion of enveloped virions in the culture medium was detected by immunoprecipitation and radioactive 
labelling of the viral genome by the endogenous viral polymerase. The migration of the genome was visualized by agarose elec-
trophoresis and PhosphorImaging (Bottom). Nonenveloped cytosolic nucleocapsids were immunoprecipitated from cell lysates 
and processed as above (Top). The amounts of virions released into the media were quantitated by measurement of the corre-
sponding band intensities and demonstrated in % amount relative to corresponding mock-treated cells (Virus production). The 
amounts of subviral envelope particles harvested from the media were measured by an S-specific ELISA and depicted as above 
(S secretion). (B) Complementation of the env-negative HBV genome with Lo mutants carrying single or double mutations in 
the preS-specific N-glycosylation sequons. HuH-7 cells were cotransfected with pHBV.env-, S, and the indicated wild-type or 
mutant Lo constructs, and intracellular nucleocapsid assembly (Top) and virus release (Bottom) were analyzed essentially as in 
A.Virology Journal 2007, 4:45 http://www.virologyj.com/content/4/1/45
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acids 3–7 of L, including the preS1 N-glycan sequon, has
been shown to block HBV infection of primary human
hepatocytes [10]. Synergistically, the preS-linked glycans
may protect the surface-exposed preS domain of L along
with its essential receptor binding site for degradation,
thereby enhancing virus stability and supporting its infec-
tivity. It is equally possible that these glycans may provide
a means to combat humoral immune surveillance in such
that they may form a formidable barrier for development
of strong antibody responses to HBV.
Methods
DNA constructs
The mammalian expression vectors carrying the HBV
(subtype ayw) L gene (pNI2.L) or S gene (pNI2.S) under
the control of the human metallothionein IIA promoter
have been described [11]. To abolish concomitant expres-
sion of the HBV M and S proteins from the L open reading
frame, their translational start codons had been inacti-
vated in the plasmid pNI2.Lo as described [29].
Site-directed mutagenesis was performed using the Quick-
Change II XL kit (Stratagene) as recommended by the
manufacturer. For simplification, amino acid numbering
used herein will refer to consecutive numbering of the L
protein rather than to the envelope protein domains (see
Fig. 1A). The N112Q mutation was introduced with the
forward primer 5'-CATCCTCAGGCCCTGCAGTGGCAAT
CCACAACCTTC-3' (nucleotides (nts) 1210–1245, muta-
tions are in boldface) and a complementary reverse
primer. For the T114A mutation, the primer 5'-CCAT-
GCAGTGGAACTCCGCAACCTTCCACC-3' (nts 1220–
1249) and its corresponding reverse primer were used.
The N4Q mutation was introduced by PCR in a two-step
reaction. First, a 150 bp product was generated using the
5'-primer 5'-CCTCCTCCAAGTCCCAGCGAACCC-3' (nts
772–795) and the mutagenic 3'-primer 5'-GCTGGT-
GGACAGCTGCTGCCCCAT-3' (nts 895–921). In a sec-
ond reaction, this product served as a 5'-primer together
with the 3'-primer 5'-TGTGATGTTCTCCATATGCAGCGC-
3' (nts 1378–1401). The resulting product was cut with
SacI and XhoI and used to substitute for the wild-type frag-
ment of pNI2.Lo. The mutation of N309Q within the S
coding region (corresponding to N146Q of S) has been
described [30]. A XhoI-SpeI-fragment containing the
N309Q mutation (nts positions 1359–19011) was sub-
cloned into the pNI2.Lo vector.
Cell culture, transfection, and lysis
In order to rule out cell type-specific effects on protein
biogenesis, we used transient expression of L in different
cell lines. COS-7 cells, HEK 293T cells, and HuH-7 liver
cells were transfected using electroporation, Lipo-
fectamine 2000 reagent (Invitrogen), or Lipofectamine/
Plus reagents (Invitrogen), respectively, as recommended
by the manufacturers. In addition, L synthesis and matu-
ration was examined in the cell line EcR-LHA-293 [21]
which stably expresses L under the control of the ecdys-
one-inducible promoter. Unless otherwise indicated, cell
lysates were prepared by incubating the cells with lysis
buffer (100 mM Tris-HCl (pH 8.0), 100 mM NaCl, 10 mM
EDTA, 1% NP-40) for 15 min on ice and cleared by cen-
trifugation at 10,000 g for 5 min at 4°C. Alternatively,
cells were disrupted by homogenization and microsomal
fractions were prepared by ultracentrifugation essentially
as described [6].
Glycosidase and tunicamycin treatment
For Peptide:N-Glycosidase F (PNGase F) treatment, cell
lysates were boiled for 10 min in denaturing buffer (0,5%
SDS, 40 mM DTT), and sodium phosphate (pH 7.5) and
NP-40 were added to give a final concentration of 50 mM
and 1%, respectively. Samples were divided in two por-
tions and incubated for 1 h at 37°C with or without 1,000
U PNGase F (New England Biolabs). For endoglycosidase
H (Endo H) digestion, cells were lysed in 50 mM Tris-HCl
(pH 7.5), 150 mM NaCl, 0,5% SDS, 1% 2-mercaptoetha-
nol and boiled for 10 min. Sodium acetate (pH 5.0) was
added at a final concentration of 50 mM and split samples
were incubated over night at 37°C with or without 5 mU
Endo H (Roche). For the tunicamycin experiment, EcR-
LHA-293 cells were treated with 10 μM of the inducer
Ponasterone A (PonA, Sigma) for 15 h in the presence or
absence of 5 μg/ml tunicamycin (Sigma).
Pulse-chase-analysis
To pulse induce L protein synthesis, EcR-LHA-293 cells
were incubated with 10 μM PonA for 3 h. After removal of
the inducer, the cells were chase treated with 0,25 mM
cycloheximide (ICN biochemicals) for different time peri-
ods. For preparation of microsomes, cells were washed
twice with Tris-buffered saline (TBS, 50 mM Tris-HCl (pH
7.5), 150 mM NaCl) and incubated for 15 min on ice with
0,1 × TBS-buffer. Microsomes were prepared by homoge-
nisation and ultracentrifugation as described [11]. The
microsomal pellet was lysed in loading buffer and sub-
jected to SDS-PAGE and immunoblotting with an L-spe-
cific monoclonal antibody recognizing an epitope within
the preS1 domain of L (MA18/7) [31].
Drug treatment of HBV-replicating cells
For replication of HBV in the HuH-7 liver cell line, plas-
mid HBV.env- was used carrying an 1.1-mer of the HBV
DNA genome [19] in which the translational start codons
for the L, M, and S envelope protein had been inactivated
by mutagenesis [29]. To allow virus production, pNI2-
based plasmids encoding HBV envelope proteins were
complemented in trans. For cotransfections, either plas-
mids pNI2.S plus pNI2.Lo or pNI2.S plus glycosylation
mutants of Lo were employed. Cells were left untreated orVirology Journal 2007, 4:45 http://www.virologyj.com/content/4/1/45
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treated for 70 h with 100 μg/ml N-butyl-deoxynojirimy-
cin (NB-DNJ, Sigma), 1 mM castanospermine (CST,
Applichem), or 5 μg/ml tunicamycin. Thereafter, cell cul-
ture supernatants were harvested and measured for the
release of subviral/viral particles by ELISA (Auszyme,
Abbott). In parallel, intracellular nucleocapsids and extra-
cellular virions were isolated by capsid- or envelope-spe-
cific immunoprecipitations, respectively, prior to
detection of the encapsidated viral progeny DNA by radi-
oactive labelling of the partially double-stranded genome
with 10 μCi [α32P]dATP (GE Healthcare) by the endog-
enous polymerase as described [29]. After extraction of
the labelled DNA genomes from the immunoprecipitated
samples, they were resolved on agarose gels and visualized
by PhosphorImaging. Band-intensities were quantified
using the ImageQuant software (Molecular Dynamics).
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